Lupin is partnering with Mark Cuban Cost Plus Drug Company and the COPD Foundation, in an effort to bolster access to health care by expanding the availability of Tiotropium Bromide Inhalation Powder, ...

The FDA on March 15 approved the first generic version of Symbicort inhalation aerosol to treat asthma and chronic obstructive pulmonary disease. The generic drug-device combination product is a ...

Inflammation that develops in chronic obstructive pulmonary disorder stems from different causes. A new regulatory decision in Europe makes Sanofi and Regeneron Pharmaceuticals drug Dupixent the first ...

Dupixent (dupilumab), a drug already used to treat atopic dermatitis and asthma, became the first biologic approved for chronic obstructive pulmonary disease (COPD) last fall. Most COPD treatments ...

A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials, ...

Researchers estimate the number of people globally living with chronic obstructive pulmonary disease (COPD) will hit 600 million by 2050. There are certain risk factors for COPD, including obesity and ...

A GSK drug that targets a pathway behind the lung inflammation in chronic obstructive pulmonary disease, or COPD, has won a long-awaited FDA approval, positioning the biologic medicine to reach ...

GSK is shelling out $85 million up front, and possibly $745 million overall, for an RNA-based therapy it sees helping a ...

-Ritedose is the development partner and manufacturer of Ohtuvayre (ensifentrine)*, the first inhaled product with a novel mechanism of action in more than 20 years for the maintenance treatment of ...

Merck is expanding its pipeline and portfolio of cardio-pulmonary disease treatments by acquiring Verona Pharma plc. The Rahway pharma giant announced the deal for the biopharmaceutical company ...